KR940019699A - 옥사졸리딘디온 유도체, 그의 제조방법 및 용도 - Google Patents

옥사졸리딘디온 유도체, 그의 제조방법 및 용도 Download PDF

Info

Publication number
KR940019699A
KR940019699A KR1019940003595A KR19940003595A KR940019699A KR 940019699 A KR940019699 A KR 940019699A KR 1019940003595 A KR1019940003595 A KR 1019940003595A KR 19940003595 A KR19940003595 A KR 19940003595A KR 940019699 A KR940019699 A KR 940019699A
Authority
KR
South Korea
Prior art keywords
substituted
oxazolidinedione
hydrocarbon residue
heterocyclic group
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1019940003595A
Other languages
English (en)
Korean (ko)
Inventor
다까시 소오다
히또시 이께다
유 모모세
사찌꼬 이마이
Original Assignee
다께다 구니오
다께다야꾸힝고오교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다께다 구니오, 다께다야꾸힝고오교 가부시끼가이샤 filed Critical 다께다 구니오
Publication of KR940019699A publication Critical patent/KR940019699A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
KR1019940003595A 1993-02-26 1994-02-26 옥사졸리딘디온 유도체, 그의 제조방법 및 용도 Abandoned KR940019699A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP3823693 1993-02-26
JP93-38236 1993-02-26
JP19730493 1993-08-09
JP93-197304 1993-08-09

Publications (1)

Publication Number Publication Date
KR940019699A true KR940019699A (ko) 1994-09-14

Family

ID=26377445

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940003595A Abandoned KR940019699A (ko) 1993-02-26 1994-02-26 옥사졸리딘디온 유도체, 그의 제조방법 및 용도

Country Status (18)

Country Link
US (4) US5665748A (enExample)
EP (1) EP0612743B1 (enExample)
JP (2) JP3328720B2 (enExample)
KR (1) KR940019699A (enExample)
CN (1) CN1098411A (enExample)
AT (1) ATE157975T1 (enExample)
AU (1) AU673034B2 (enExample)
CA (1) CA2116387C (enExample)
DE (1) DE69405425T2 (enExample)
DK (1) DK0612743T3 (enExample)
ES (1) ES2108375T3 (enExample)
FI (1) FI940904A7 (enExample)
GR (1) GR3025342T3 (enExample)
HU (1) HUT70159A (enExample)
NO (1) NO305079B1 (enExample)
PH (1) PH31468A (enExample)
RU (1) RU2126797C1 (enExample)
TW (1) TW268952B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468762A (en) * 1994-05-18 1995-11-21 American Home Products Corporation Azolidinediones as antihyperglycemic agents
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
TW403748B (en) * 1994-11-02 2000-09-01 Takeda Chemical Industries Ltd An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
CA2171702A1 (en) * 1995-03-14 1996-09-15 Takashi Sohda Benzofuran compounds and their use
JPH09136877A (ja) * 1995-06-16 1997-05-27 Takeda Chem Ind Ltd 複素環化合物、その製造法及び用途
AU2177797A (en) 1996-04-03 1997-10-22 Takeda Chemical Industries Ltd. Oxazole derivatives, their production and use
JPH09323930A (ja) * 1996-04-04 1997-12-16 Takeda Chem Ind Ltd 悪液質の予防・治療剤
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
ZA973848B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them.
US5889025A (en) * 1996-05-06 1999-03-30 Reddy's Research Foundation Antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
FR2749583B1 (fr) * 1996-06-07 1998-08-21 Lipha Nouveaux derives de thiazolidine -2,4- dione substitues, leurs procedes d'obtention et les compositions pharmaceutiques en renfermant
US6372750B2 (en) 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
US6114526A (en) * 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
USRE39266E1 (en) * 1996-07-01 2006-09-05 Dr. Reddy's Laboratories, Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US5985884A (en) * 1996-07-01 1999-11-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
EE03765B1 (et) 1996-08-19 2002-06-17 Japan Tobacco Inc. Propioonhappe derivaadid ja nende kasutamine
US6011036A (en) * 1997-04-15 2000-01-04 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic hypolipidemic antihypertensive properties process for their preparation and pharmaceutical compositions containing them
US6011031A (en) * 1997-05-30 2000-01-04 Dr. Reddy's Research Foundation Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
CN1312807A (zh) 1998-06-19 2001-09-12 希龙公司 糖元合成酶激酶3的抑制剂
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
CN1053186C (zh) * 1998-07-09 2000-06-07 华东理工大学 喹啉噁唑啉化合物
JP2000044551A (ja) * 1998-07-27 2000-02-15 Konica Corp ３−置換−３−オキソ−２−（２，４−オキサゾリジンジオン−３−イル）プロピオン酸アミド化合物の製造方法
AU6331199A (en) * 1998-09-30 2000-04-17 Roche Diagnostics Gmbh Oxazolidine derivatives for the treatment and prevention of metabolic bone disorders
US6121300A (en) * 1998-11-10 2000-09-19 Wagle; Dilip R. Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts
AU776299B2 (en) * 1998-12-01 2004-09-02 Dr Reddy's Laboratories, Inc. New pharmaceutical composition and the process for its preparation
ID30498A (id) 1999-04-07 2001-12-13 Sankyo Co Senyawa-senyawa turunan amina
ATE333448T1 (de) 1999-06-18 2006-08-15 Merck & Co Inc Arylthiazolidinedione und aryloxa zolidinedion- derivate
CA2377246A1 (en) 1999-06-18 2000-12-28 Ranjit C. Desai Arylthiazolidinedione and aryloxazolidinedione derivatives
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
JP4316787B2 (ja) * 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
US7105551B2 (en) 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
WO2002076959A1 (en) * 2001-03-23 2002-10-03 Takeda Chemical Industries, Ltd. Five-membered heterocyclic alkanoic acid derivative
TW200300681A (en) * 2001-11-12 2003-06-16 Ono Pharmaceutical Co Carboxylic acid derivative compound and medicament containing same as active ingredient
AU2003203170A1 (en) * 2002-01-17 2003-07-30 Takeda Chemical Industries, Ltd. Nitrogenous heterocyclic compounds, process for preparation of the same and use thereof
TWI327462B (en) * 2002-01-18 2010-07-21 Sumitomo Chemical Co Condensed heterocyclic sulfonyl urea compound, a herbicide containing the same, and a method for weed control using the same
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US7521465B2 (en) * 2003-01-17 2009-04-21 Bexel Pharmaceuticals, Inc. Diphenyl ether derivatives
US6794401B2 (en) * 2003-01-17 2004-09-21 Bexel Pharmaceuticals, Inc. Amino acid phenoxy ethers
US7781464B2 (en) * 2003-01-17 2010-08-24 Bexel Pharmaceuticals, Inc. Heterocyclic diphenyl ethers
KR20060006953A (ko) 2003-04-30 2006-01-20 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 치환된 카르복실산
US7087576B2 (en) * 2003-10-07 2006-08-08 Bexel Pharmaceuticals, Inc. Dipeptide phenyl ethers
NZ548556A (en) * 2004-01-20 2009-03-31 Merck & Co Inc Antidiabetic oxazolidinediones and thiazolidinediones as agonists or partial agonists of PPAR gamma
JP2008518926A (ja) * 2004-10-28 2008-06-05 ジ インスティチューツ フォー ファーマシューティカル ディスカバリー、エルエルシー 置換フェニルアルカン酸
TW200932219A (en) * 2007-10-24 2009-08-01 Astellas Pharma Inc Oxadiazolidinedione compound
US11746354B2 (en) 2019-07-19 2023-09-05 Inari Agriculture Technology, Inc. Homology dependent repair genome editing
WO2026008867A1 (en) * 2024-07-04 2026-01-08 Institut National de la Santé et de la Recherche Médicale Novel inhibitors of acsl4 and their use as medicines

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4430337A (en) * 1982-06-23 1984-02-07 Pfizer Inc. Alicyclic substituted oxazolidine-2,4-diones having hypoglycemic activity
US5232925A (en) * 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
US5061717A (en) * 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
US5143930A (en) * 1990-02-07 1992-09-01 Sankyo Company, Limited Thiazolidine derivatives with anti-diabetic activity, their preparation and their use
JP2991801B2 (ja) * 1990-04-27 1999-12-20 三共株式会社 ベンジリデンチアゾリジン化合物
US5037842A (en) 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
GB9017218D0 (en) * 1990-08-06 1990-09-19 Beecham Group Plc Novel compounds
SK109993A3 (en) * 1991-04-11 1994-12-07 Upjohn Co Thiazolidinedione derivatives producing and use thereof
DK0597102T3 (da) * 1991-07-30 1999-08-09 Yamanouchi Pharma Co Ltd Nyt bisheterocyklisk derivat og salt heraf samt hypoglykæmisk sammensætning
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
ATE194981T1 (de) * 1992-04-30 2000-08-15 Taiho Pharmaceutical Co Ltd Oxazolidinderivat und sein pharmazeutisch verträgliches salz
US5928152A (en) * 1994-08-05 1999-07-27 Acuson Corporation Method and apparatus for a baseband processor of a receive beamformer system

Also Published As

Publication number Publication date
RU2126797C1 (ru) 1999-02-27
US5665748A (en) 1997-09-09
HUT70159A (en) 1995-09-28
ATE157975T1 (de) 1997-09-15
HU9400578D0 (en) 1994-05-30
FI940904L (fi) 1994-11-29
CN1098411A (zh) 1995-02-08
CA2116387C (en) 2003-12-23
TW268952B (enExample) 1996-01-21
AU5515894A (en) 1994-09-01
DE69405425T2 (de) 1998-03-19
ES2108375T3 (es) 1997-12-16
NO305079B1 (no) 1999-03-29
GR3025342T3 (en) 1998-02-27
CA2116387A1 (en) 1994-08-27
JP3328720B2 (ja) 2002-09-30
US6552058B1 (en) 2003-04-22
AU673034B2 (en) 1996-10-24
NO940610L (no) 1994-08-29
DK0612743T3 (da) 1998-04-20
US6147099A (en) 2000-11-14
EP0612743B1 (en) 1997-09-10
DE69405425D1 (de) 1997-10-16
US5972970A (en) 1999-10-26
JPH07165735A (ja) 1995-06-27
JP2000191651A (ja) 2000-07-11
FI940904A7 (fi) 1994-11-29
PH31468A (en) 1998-11-03
NO940610D0 (no) 1994-02-23
FI940904A0 (fi) 1994-02-25
EP0612743A1 (en) 1994-08-31

Similar Documents

Publication Publication Date Title
KR940019699A (ko) 옥사졸리딘디온 유도체, 그의 제조방법 및 용도
KR960017648A (ko) 옥사졸리딘디온 유도체, 그의 제법 및 용도
KR890014533A (ko) 혈당 감소제 티아졸리딘디온 유도체
KR950702982A (ko) 치환된 티아졸리딘디온 유도체(Substituted Thiazolidinedione Derivatives)
KR940006590A (ko) 알쯔하이머 질환 치료용 및 혈당저하제로서 유용한 화합물
JP5261383B2 (ja) ヒトプロテインチロシンホスファターゼ阻害剤および使用法
RU2312106C2 (ru) Замещенные 4-алкоксиоксазолпроизводные в качестве агонистов ppar
RU95118725A (ru) Производные оксазолидиндиона, их получение и фармацевтическая композиция
RU92004433A (ru) Ароматические аминоспиртовые производные, способ их получения и фармацевтическая композиция
RU2000131183A (ru) Производные оксииминоалкановой кислоты
CA2192092A1 (en) Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors
DK200001556A (da) Substituerede thiazolidindionderivater
RU2000100951A (ru) Имидазолил-циклические ацетали
RU2002115263A (ru) 5-членные N-гетероциклические соединения, обладающие гипогликемической и гиполипидемической активностью
KR950701328A (ko) 메일라드 반응 억제제로서의 티아졸 또는 이미다졸 유도체(Thiazole or imidazole derivatives as Maillard reaction inhibitors)
KR890003742A (ko) 카르바모일키롤리돈 유도체 및 노인성 치매용 약제
JP2006516251A5 (enExample)
KR930702288A (ko) 타이졸리딘디온 유도체
KR890000477A (ko) 신규 화합물들
JP2005526696A5 (enExample)
KR890014534A (ko) 혈당 감소제로서 티아졸리딘디온 유도체
JPH08509486A (ja) アテローム性動脈硬化症および食事障害の治療についてのチアゾリジンジオンの使用
KR950702997A (ko) 포스폰산 디에스테르 유도체(phosphonic diester derivative)
KR830009066A (ko) 티아졸 유도체의 제조방법
AU710249B2 (en) Autoimmune disease therapeutic agent

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee

St.27 status event code: A-2-2-U10-U13-oth-PC1904

St.27 status event code: N-2-6-B10-B12-nap-PC1904

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000